Fulcrum Therapeutics (NASDAQ:FULC – Get Free Report) is scheduled to be issuing its quarterly earnings data before the market opens on Wednesday, July 31st. Analysts expect the company to announce earnings of ($0.06) per share for the quarter. Parties that wish to listen to the company’s conference call can do so using this link.
Fulcrum Therapeutics (NASDAQ:FULC – Get Free Report) last posted its quarterly earnings results on Monday, May 13th. The company reported ($0.43) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.01. Fulcrum Therapeutics had a negative net margin of 3,470.05% and a negative return on equity of 40.60%. On average, analysts expect Fulcrum Therapeutics to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Fulcrum Therapeutics Price Performance
FULC stock remained flat at $8.43 during trading on Tuesday. 122,985 shares of the company traded hands, compared to its average volume of 699,351. Fulcrum Therapeutics has a 52 week low of $3.14 and a 52 week high of $13.70. The firm has a 50-day moving average of $7.45 and a 200 day moving average of $8.18.
Wall Street Analyst Weigh In
Get Our Latest Analysis on FULC
Fulcrum Therapeutics Company Profile
Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.
Further Reading
- Five stocks we like better than Fulcrum Therapeutics
- Investing in Commodities: What Are They? How to Invest in Them
- AbbVie Analysts Lead the Stock Higher as Humira Worries Recede
- The 3 Best Retail Stocks to Shop for in August
- Harley-Davidson Stock Revs Up With Billion Dollar Buyback Program
- How to Calculate Return on Investment (ROI)
- Cruise Line Stock Sinks Despite Beating EPS and Raised Guidance
Receive News & Ratings for Fulcrum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulcrum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.